These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27572335)

  • 1. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
    Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
    Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
    Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
    Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
    Roila F; Warr D; Hesketh PJ; Gralla R; Herrstedt J; Jordan K; Aapro M; Ballatori E; Rapoport B
    Support Care Cancer; 2017 Jan; 25(1):289-294. PubMed ID: 27510316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
    Herrstedt J; Roila F; Warr D; Celio L; Navari RM; Hesketh PJ; Chan A; Aapro MS
    Support Care Cancer; 2017 Jan; 25(1):277-288. PubMed ID: 27443154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
    Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
    Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
    Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
    Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
    Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
    McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
    Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Warr D; Hesketh PJ
    Support Care Cancer; 2017 Jan; 25(1):271-275. PubMed ID: 27501965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy induced emesis: pathophysiology and prevention].
    Mailliez A; Bonneterre J
    Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Ruhlmann CH; Sayegh P; Hesketh PJ
    Support Care Cancer; 2023 Dec; 32(1):53. PubMed ID: 38129530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
    Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Jordan K; Jahn F; Maranzano E; Molassiotis A; Dennis K
    Support Care Cancer; 2023 Dec; 32(1):26. PubMed ID: 38097904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
    De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
    Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
    Ann Oncol; 1998 Aug; 9(8):811-9. PubMed ID: 9789602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emesis induced by low or minimal emetic risk chemotherapy.
    Tonato M; Clark-Snow RA; Osoba D; Del Favero A; Ballatori E; Borjeson S
    Support Care Cancer; 2005 Feb; 13(2):109-11. PubMed ID: 15714358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.